BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Migraine clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for migraine: 66 (28 sponsors; 16 newly posted in the last 180 days, 5 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 25, rank 12 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 1, Phase 2 5, Phase 3 29, Phase 4 5, N/A 26.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AbbVie ABBV13NA 5, P3 7, P2 113
Pfizer PFE14NA 5, P4 2, P3 6, P1 142
H. Lundbeck A/S3P3 301
TriGemX Bio, Inc. new entrant3P3 331
Ipsen3P2 1, P3 200
Brise Pharmaceuticals Co., Ltd. new entrant2P3 220
Eli Lilly and Company LLY2P3 200
Merz Therapeutics GmbH2P3 202
Amgen AMGN2NA 1, P3 100
Dr George Medvedev1P3 100
Salvia BioElectronics3NA 311
Theranica2NA 1, P4 110
Abilion Medical Systems AB1NA 100
Alasht Pharmed1P4 100
Aspeya, Inc. new entrant1P2 111
Brightmind.AI1NA 100
Cefaly Technology1NA 101
Cerenovus, Part of DePuy Synthes Products, Inc.1NA 101
Cortex Neurovascular new entrant1NA 110
Danone Nutricia SpA Società Benefit1NA 100
Evommune, Inc. EVMN new entrant1P2 110
Hinge Health, Inc HNGE new entrant1NA 110
Libbs Farmacêutica LTDA1NA 100
Otsuka Pharmaceutical Co., Ltd.1NA 100
Power Life Sciences Inc.1NA 100

New-entrant sponsors: TriGemX Bio, Inc., Brise Pharmaceuticals Co., Ltd., Aspeya, Inc., Cortex Neurovascular, Evommune, Inc., Hinge Health, Inc.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-29 est.P3Pfizer PFENCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineMenstrual Migrainerecruiting723
2027-02 est.P2AbbVie ABBVNCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineMigraineactive not recruiting309
2027-02 est.P3TriGemX Bio, Inc.NCT07645924 A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineMigrainerecruiting1800

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09 est.P2Sichuan Purity Pharmaceutical Technology Co., Ltd.NCT07304518 Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in AdultsMigrainerecruiting456
2026-06-29P3AbbVie ABBVNCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineMenstrual Migraine (MM)active not recruiting468
2026-06-01P3IpsenNCT06047457 A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsEpisodic Migraineactive not recruiting751
2026-05-28P3IpsenNCT06047444 A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsChronic Migraineactive not recruiting759

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "migraine"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.